НовостиBenzingaWedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 Benzinga 2026.10.27 14:10 (GMT+0) Открыть на Benzinga Другие новости